Global Cell and Gene Therapy Market to Reach $29.15 Billion by 2029, Growing at 17.1% CAGR

"Which drivers are expected to have the greatest impact on the over the cell and gene therapy market's growth?
Continual financing and integration within the field of cell and gene therapies have significantly driven the growth of the cell and gene therapy (CGT) market. Recognizing the potential of CGT, 16 of the 20 largest revenue-generating biopharmaceutical firms have incorporated CGT products into their offerings. As an example, UK cell and gene therapy firms, in 2023, acquired over 55% of venture capital funding gained by European businesses, as per the UK's BioIndustry Association (BIA), an entity representing the biotech and life sciences industry. Generally, the UK accounts for about one-third of all European life sciences venture capital investments, underlining its strong stance in the cell and gene therapy sector. Persistent investment and consolidation of CGT production capacity resulted in an increased production capacity and further propelled market growth. For instance, in October 2024, UK biotech firm Purespring Therapeutics secured $105 million funding to bolster the development of gene therapies for kidney diseases, including a phase 1/2 trial of a treatment under study for immunoglobulin A nephropathy (IgAN). Purespring employs adeno-associated viruses (AAVs) for the delivery of its gene therapies into the body.

Get Your Cell and Gene Therapy Market Report Here:
https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

What is the future CAGR of the cell and gene therapy market, and how will it impact industry expansion?
In recent times, the cell and gene therapy market has witnessed a considerable expansion. Forecasts indicate that it will surge from $12.01 billion in 2024 to $15.48 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 28.9%. This significant growth in the preceding years has been propelled by factors including amplified investments in cell and gene therapies, the expansion of research and development, advancements in cancer drug discovery, an uptick in public-private partnerships, robust economic progression in budding markets, elevated healthcare spending, and a rise in R&D expenditure in the pharmaceutical sector.

The market for cell and gene therapy is projected to experience considerable expansion in the coming years, hitting $29.15 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 17.1%. This surge during the forecast period is due to the escalating frequency of cancer and chronic diseases, a growing elderly population, increased attention to cell and gene therapy, and a sharp rise in healthcare spending. The future trends are set to focus more on sophisticated therapies like Chimeric Antigen Receptor (CAR) T-cell therapy, intensifying various research initiatives and securing funding, strategic collaborations to incorporate advanced technologies, focus on crafting gene or genome editing tools particularly CRISPR, partnerships or acquisitions of rival companies, heightening the quantity of pipeline research for cell and gene therapy development, and investments in the expansion of manufacturing facilities.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

What are the most significant trends transforming the cell and gene therapy market today?
The cell and gene therapy (CGT) market is being significantly shaped by Chimeric antigen receptor (CAR) T-cell therapy. In this therapy, T cells are harvested from the patient's blood and genetically reprogrammed to yield unique receptors on their surfaces, which are known as chimeric antigen receptors (CARs). The restructured T cells equipped with specialized receptors are then reintroduced into the patient's body. The engineered receptors on T cells play a crucial role in identifying the surface antigen on cancer cells, thereby killing tumor cells effectively. For example, Bristol-Myers Squibb Company, an American pharmaceutical firm, received authorization from the United States Food and Drug Administration (US FDA) in June 2022 for their CAR T cell therapy Breyanzi, used in treating adult patients suffering from large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma. Breyanzi is a unique CAR T cell therapy derived from a patient's own T cells, which are procured, genetically reprogrammed into CAR T cells, and then delivered back to the patient as a solitary treatment.

Which key market segments comprise the cell and gene therapy market and drive its revenue growth?
The cell and gene therapy market covered in this report is segmented -

1) By Product: Cell Therapy, Gene Therapy
2) By Application: Oncology, Neurological Disorders, Other Applications
3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

Subsegments:
1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy
2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3472

What regions are at the forefront of cell and gene therapy market expansion?
North America was the largest region in the cell and gene therapy market in 2024. The regions covered in the cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Who are the leading players fueling growth in the cell and gene therapy market?
Major companies operating in the cell and gene therapy market include Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Biocon, Cipla, Stempeutics Research Pvt. Ltd., EdiGene Inc., Immunochina, Takara Bio, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Oxford Biomedica plc, Santen Pharmaceutical Co., Therapeutic Innovation Australia, Merck, GenScript, Cellular Biomedicine Group, GE Healthcare, inStem, Lonza, Nikon CeLL innovation Co. Ltd., Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Oxford BioTherapeutics, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

What Is Covered In The Cell and Gene Therapy Global Market Report?

•Market Size Forecast: Examine the cell and gene therapy market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the cell and gene therapy market for a structured understanding.
•Key Players Overview: Analyze major players in the cell and gene therapy market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the cell and gene therapy market.
•Segment Contributions: Evaluate how different segments drive overall growth in the cell and gene therapy market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the cell and gene therapy market.
•Industry Challenges: Identify potential risks and obstacles affecting the cell and gene therapy market.
•Competitive Landscape: Review strategic developments in the cell and gene therapy market, including expansions, agreements, and new product launches.

"

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
•LinkedIn: https://in.linkedin.com/company/the-business-research-company
•Twitter: https://twitter.com/tbrc_info
•YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead

This release was published on openPR.